ArticleMolecular cancer2015
Identification of a blood-borne miRNA signature of synovial sarcoma.
Article in Molecular cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 52 citations in OpenAlex.
- Circulating Biomarkers in Sarcoma.Current oncology reports · 2025Review
- Dysregulation of miRNAs in Soft Tissue Sarcomas.Cells · 2024Review
- Ago2/CAV1 interaction potentiates metastasis via controlling Ago2 localization and miRNA action.EMBO reports · 2024Article
- The application of lung immune prognostic index in predicting the prognosis of 302 STS patients.Frontiers in oncology · 2024Article
- The Roles of Exosomes in Metastasis of Sarcoma: From Biomarkers to Therapeutic Targets.Biomolecules · 2023Review
- Article
- Genotyping of Circulating Free DNA Enables Monitoring of Tumor Dynamics in Synovial Sarcomas.Cancers · 2022Article
- Accuracy of core needle biopsy for histologic diagnosis of soft tissue sarcoma.Scientific reports · 2022Article
- Altered Expressions of NF1 and NF1-Related microRNAs as Biomarkers in the Diagnosis of Undifferentiated Pleomorphic Sarcoma.Frontiers in genetics · 2022Article
- miRNAs as Biomarkers and Possible Therapeutic Strategies in Synovial Sarcoma.Frontiers in pharmacology · 2022Review
- Soft Tissue Sarcoma: An Insight on Biomarkers at Molecular, Metabolic and Cellular Level.Cancers · 2021Review
- CircMACF1 Attenuates Acute Myocardial Infarction Through miR-500b-5p-EMP1 Axis.Journal of cardiovascular translational research · 2021Article
- Synovial Sarcoma: A Complex Disease with Multifaceted Signaling and Epigenetic Landscapes.Current oncology reports · 2020Review
- Clinical relevance and functional significance of cell-free microRNA-1260b expression profiles in infiltrative myxofibrosarcoma.Scientific reports · 2020Article
- Identifying specific miRNAs and associated mRNAs in CD44 and CD90 cancer stem cell subtypes in gastric cancer cell line SNU-5.International journal of clinical and experimental pathology · 2020Article
- Article
- The new horizon of liquid biopsy in sarcoma: the potential utility of circulating tumor nucleic acids.Journal of Cancer · 2020Review
- miR-195 Serves as a Tumor Suppressor in the Progression of Liposarcoma by Targeting OSBP.OncoTargets and therapy · 2020Article
- HNRNPA2/B1 is upregulated in endocrine-resistant LCC9 breast cancer cells and alters the miRNA transcriptome when overexpressed in MCF-7 cells.Scientific reports · 2019Article
- A serum microRNA classifier for the diagnosis of sarcomas of various histological subtypes.Nature communications · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSynovial sarcoma account for approximately 10 % of all soft-tissue tumors and occur most frequently in young adults. A specific translocation in this sarcoma induces fusion of the SYT gene on chromosome 18 to the SSX genes on chromosome X, leading to proliferation of the tumor cells. The need for non-invasive biomarkers indicating recurrence and activity of this disease has sparked research into short non-coding RNA known as microRNA (miRNA).
methodsBlood samples of patients with active synovial sarcoma and of synovial sarcoma patients in complete remission as well as of healthy donors and patients with active leiomyosarcoma, MPNST, Ewing sarcoma and liposarcoma were collected. Whole blood RNA was extracted and samples of patients with active synovial sarcoma and of healthy donors were analyzed using an Affymetrix GeneChip miRNA Array v. 4.0. qRT-PCR was carried out to confirm a panel of miRNAs which where differentially expressed in the miRNA array. This miRNA-panel was further evaluated in patients with synovial sarcoma in complete remission and patients with active leiomyosarcoma, MPNST, Ewing sarcoma and liposarcoma as well as in an independent cohort of synovial sarcoma patients.
resultsUnsupervised hierarchical clustering of the miRNA arrays separated patients with active synovial sarcoma from healthy controls. A panel of seven miRNAs (miR-99a-5p, miR-146b-5p, miR-148b-3p, miR-195-5p, miR-223-3p, miR-500b-3p and miR-505-3p) was further validated by qRT-PCR to be significantly upregulated in synovial sarcoma patients. Moreover, most of the analyzed miRNAs were shown to be significantly upregulated in synovial sarcoma patients compared to leiomyosarcoma, MPNST, Ewing sarcoma and liposarcoma patients. Validation of the miRNA panel in an independent cohort of synovial sarcoma patients confirmed higher expression levels compared to healthy controls and patients in complete remission.
conclusionOur results have identified a specific whole blood miRNA signature that may serve as an independent biomarker for the diagnosis of local recurrence or distant metastasis of synovial sarcoma. It even distinguishes synovial sarcoma from other sarcoma subtypes, thus potentially serving as a specific biomarker for synovial sarcoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.